Abstract
Multimodal graph learning techniques have demonstrated significant potential in modeling brain networks for Alzheimer’s disease (AD) detection. However, most existing methods rely on Euclidean space representations and overlook the scale-free and small-world properties of brain networks, which are characterized by power-law distributions and dense local clustering of nodes. This oversight results in distortions when representing these complex structures. To address this issue, we propose a novel multimodal Poincaré Fréchet mean graph convolutional network (MochaGCN) for AD detection. MochaGCN leverages the exponential growth characteristics of hyperbolic space to capture the scale-free and small-world properties of multimodal brain networks. Specifically, we combine hyperbolic graph convolution and Poincaré Fréchet mean to extract features from multimodal brain networks, enhancing their rep-resentations in hyperbolic space. Our approach constructs multimodal brain networks by integrating information from diffusion tensor imaging (DTI) and functional magnetic resonance imaging (fMRI) data. Experiments on the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset demonstrate that the proposed method outperforms state-of-the-art techniques.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://adni.loni.usc.edu/data-samples/adni-data/ The ADNI data set is a comprehensive and widely used collection of longitudinal clinical, imaging, genetic, and other biomarker data. It encompasses various data types, including structural, functional, and molecular brain imaging, biofluid biomarkers, cognitive assessments, genetic data, and demographic information. ADNI participants are assigned to a Schedule of Events (SOE) based on various factors, such as clinical diagnosis (unimpaired, MCI, AD/dementia). During each visit, the SOE dictates what data is collected. This data is made available to approved researchers.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵✉ f.xia{at}ieee.org
{chengyao.xie{at}federation.edu.au, ciyuan.peng{at}federation.edu.au, a.noorihoshyar{at}federation.edu.au}, wenhaozhou{at}stu.ahu.edu.cn, chengpei.xu{at}unsw.edu.au, usman.naseem{at}mq.edu.au, usman.naseem{at}mq.edu.au
Change paper type to latex
Data Availability
All data produced are available online at https://adni.loni.usc.edu/data-samples/adni-data/
